Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...

Despite the setback, Vertex continues to develop another T1D therapy, zimislecel, which is currently being investigated in a Phase III trial (NCT04786262). Zimislecel is administered alongside ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Ver­tex Phar­ma­ceu­ti­cals an­nounced Fri­day af­ter­noon that it won’t move for­ward with its type 1 di­a­betes cell ther­a­py that’s de­liv­ered in a … ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes ...

Vertex plans to conduct further analyses, including of explanted devices, to better understand these findings. Zimislecel (formerly VX-880), Vertex’s investigational fully differentiated islet cell ...